• Product NameRegadenoson
• Brief DescriptionInhibitors
• Purification99.78%
• Biological ActivityRegadenoson is an adenosine derivative and selective A2A adenosine receptor agonist with coronary vasodilating activity. Upon administration, regadenoson selectively binds to and activates the A2A adenosine receptor, which induces coronary vasodilation. This leads to an increase in coronary blood flow and enhances myocardial perfusion. Compared to adenosine, regadenoson has a longer half-life and shows higher selectivity towards the A2A adenosine receptor. This agent is a very weak agonist for the A1 adenosine receptor and has negligible affinity for the A2B and A3 adenosine receptors.
• Target NameAdenosine Receptor agonist
• CAS No. 313348-27-5
• Calculated MW 390.35
• Formulation C15H18N8O5
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cardiovascular System
  SMILES:CNC(=O)C1=CN(N=C1)C2=NC3=C(C(=N2)N)N=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
  Pathways:GPCR/G Protein
  Receptor:A2A
  Boling pt:
  Melting pt:158-160C
  Solubility:DMSO: 10 mM
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Zoghbi GJ, Iskandrian AE. J Nucl Cardiol. 2012 Feb;19(1):126-41.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting